ITERUM THERAPEUTICS PLC (ITRM)
IE000TTOOBX0 - Common Stock
Iterum Therapeutics Regains Full Nasdaq Compliance
Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market...
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 ...
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
/PRNewswire/ -- WHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of...
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to...
Iterum Therapeutics to Present Data at IDWeek 2024
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company...
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on...
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company...
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q2 2024
ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Iterum Therapeutics (NASDAQ:ITRM) just reported results for the second quarter ...
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
-- FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— --Cash Runway into 2025, including through PDUFA Action...
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company...
Iterum Therapeutics Announces Expiration and Results of Rights Offering
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company...
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on...
Iterum Therapeutics Commences Rights Offering
DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company...
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Proposed Date for Advisory Committee meeting is September 9, 2024
Iterum Therapeutics to Present Data at ASM Microbe 2024
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company...
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024...
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024
ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Iterum Therapeutics (NASDAQ:ITRM) just reported results for the first quarter o...
Iterum Therapeutics Reports First Quarter 2024 Financial Results
--NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host...
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN,...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023
ITRM stock results show that Iterum Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023.
ITRM Stock Earnings: Iterum Therapeutics Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Iterum Therapeutics (NASDAQ:ITRM) just reported results for the fourth quarter ...
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
--Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host...
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical...
Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat
DUBLIN, Ireland and CHICAGO, March 15, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company...
Iterum meets main goal in late trial for uUTI treatment with oral sulopenem (NASDAQ:ITRM)
Iterum Therapeutics announced positive results from a phase 3 trial comparing oral sulopenem to Augmentin in women with urinary tract infections.